How big is the liver fibrosis market | Size, Share & Growth Outlook 2025

How big is the Liver Fibrosis Market?

The market is expanding due to rising incidence of chronic liver diseases, increasing alcohol consumption, growing obesity rates, and advances in non-invasive diagnostic technologies and antifibrotic drug development.

Key Growth Drivers of the Liver Fibrosis Market

• Rising global burden of chronic hepatitis B and C infections
• Increasing prevalence of non-alcoholic fatty liver disease (NAFLD) and NASH
• Advances in non-invasive diagnostic tools like transient elastography and serum biomarkers
• Strong R&D pipeline for antifibrotic therapies and targeted treatments
• Growing awareness and screening programs for early-stage liver damage detection

Liver Fibrosis Market Trends

Liver fibrosis market is witnessing trends such as a strong focus on developing antifibrotic drugs targeting multiple molecular pathways, greater reliance on AI-enhanced imaging for staging and monitoring, and increased adoption of non-invasive testing to replace liver biopsies. Trends that pharmaceutical firms are coming up with a strategy of combination therapeutics, and population health initiatives are driving the focus on lifestyle interventions to have a prevention of the disease advancement. Digital health also has the potential of improving patient adherence and monitoring by integrating health tools.

Emerging Developments in the Liver Fibrosis Market

Liver fibrosis market is experiencing developments such as regulatory fast-tracking of promising antifibrotic candidates, collaborations between biotech firms and academic institutions to accelerate clinical research and expanding clinical trials for therapies aimed at reversing fibrosis. Future care models are being developed through the use of machine learning algorithms in predictive diagnostics, new developments in regenerative medicine and custom treatment plans built off genetic profiling. Moreover, collaboration with medical facilities is facilitating the greater availability of diagnostic technologies on the emerging markets.

List of Leading Companies in the Liver Fibrosis Market

Below is a comprehensive list of the leading market players driving growth in this sector:

1. Gilead Sciences, Inc.

Gilead Sciences develops innovative therapies targeting liver fibrosis, with a strong focus on antiviral drugs, NASH treatments, and global patient access initiatives.

2. Intercept Pharmaceuticals, Inc.

Intercept is dedicated to progressive liver disease solutions, offering leading drugs for primary biliary cholangitis and conducting trials for NASH-related fibrosis.

3. Bristol Myers Squibb Company

Bristol Myers Squibb works on targeted therapies for liver fibrosis, leveraging immunomodulators and antifibrotic compounds to address chronic liver disease progression.

4. Novo Nordisk A/S

Novo Nordisk applies metabolic research expertise to develop treatments for NASH-induced fibrosis, aiming to halt disease progression and improve liver health outcomes.

5. Pfizer Inc.

Pfizer is engaged in clinical trials for antifibrotic drugs targeting NASH and hepatitis-related liver scarring, focusing on innovative molecular pathways for therapy.

6. Genfit SA

Genfit specializes in diagnostics and therapeutics for NASH and fibrosis, integrating biomarker development with precision medicine to advance patient-specific solutions.

7. Madrigal Pharmaceuticals, Inc.

Madrigal focuses on metabolic liver diseases, developing compounds that reduce fibrosis and address underlying metabolic dysfunction in NASH patients globally.

8. Galectin Therapeutics Inc.

Galectin Therapeutics develops galectin inhibitors aimed at reversing fibrosis and treating NASH, prioritizing advanced-stage patients with unmet medical needs.

9. Conatus Pharmaceuticals Inc.

Conatus research oral drugs for chronic liver diseases, particularly targeting inflammation and fibrotic pathways to slow or reverse liver tissue damage.

10. Takeda Pharmaceutical Company Limited

Takeda pursues treatments for rare and chronic liver fibrosis conditions, combining global research networks with expertise in inflammation and metabolic diseases.

How big is the liver fibrosis market : FAQs